MYCN and Metabolic Reprogramming in Neuroblastoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Sep 9

PMID 36077650

Authors

Mohit Bansal

Anamika Gupta

Han-Fei Ding

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a pediatric cancer responsible for approximately 15% of all childhood cancer deaths. Aberrant MYCN activation, as a result of genomic amplification, is a major driver of high-risk neuroblastoma, which has an overall survival rate of less than 50%, despite the best treatments currently available. Metabolic reprogramming is an integral part of the growth-promoting program driven by MYCN, which fuels cell growth and proliferation by increasing the uptake and catabolism of nutrients, biosynthesis of macromolecules, and production of energy. This reprogramming process also generates metabolic vulnerabilities that can be exploited for therapy. In this review, we present our current understanding of metabolic reprogramming in neuroblastoma, focusing on transcriptional regulation as a key mechanism in driving the reprogramming process. We also highlight some important areas that need to be explored for the successful development of metabolism-based therapy against high-risk neuroblastoma.

Citing Articles

Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor.

Jablonowski C, Quarni W, Singh S, Tan H, Hewa Bostanthirige D, Jin H Elife. 2024; 12.

PMID: 38488852 PMC: 10942784. DOI: 10.7554/eLife.90993.

A prognostic metabolism-related gene signature associated with the tumor immune microenvironment in neuroblastoma.

Yu X, Xu C, Zou Y, Liu W, Xie Y, Wu C Am J Cancer Res. 2024; 14(1):253-273.

PMID: 38323276 PMC: 10839309.

Functionalized GD2 Electrochemical Immunosensor to Diagnose Minimum Residual Disease of Bone Marrow in Neuroblastoma Effectively.

Chen C, Hu C, He B, Bai Y, He F, Li S Biosensors (Basel). 2023; 13(10).

PMID: 37887113 PMC: 10605222. DOI: 10.3390/bios13100920.

Amplifications and Metabolic Rewiring in Neuroblastoma.

Pouliou M, Koutsi M, Champezou L, Giannopoulou A, Vatsellas G, Piperi C Cancers (Basel). 2023; 15(19).

PMID: 37835497 PMC: 10571721. DOI: 10.3390/cancers15194803.

The Illustration of Altered Glucose Dependency in Drug-Resistant Cancer Cells.

Bishayee K, Lee S, Park Y Int J Mol Sci. 2023; 24(18).

PMID: 37762231 PMC: 10530558. DOI: 10.3390/ijms241813928.

References

Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G . Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids. 2013; 45(3):463-77. DOI: 10.1007/s00726-013-1493-1. View

Grandori C, Cowley S, James L, Eisenman R . The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000; 16:653-99. DOI: 10.1146/annurev.cellbio.16.1.653. View

Alborzinia H, Florez A, Kreth S, Bruckner L, Yildiz U, Gartlgruber M . MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer. 2022; 3(4):471-485. PMC: 9050595. DOI: 10.1038/s43018-022-00355-4. View

Choi B, Coloff J . The Diverse Functions of Non-Essential Amino Acids in Cancer. Cancers (Basel). 2019; 11(5). PMC: 6562791. DOI: 10.3390/cancers11050675. View

Ameri K, Harris A . Activating transcription factor 4. Int J Biochem Cell Biol. 2007; 40(1):14-21. DOI: 10.1016/j.biocel.2007.01.020. View

Qing G, Li B, Vu A, Skuli N, Walton Z, Liu X . ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012; 22(5):631-44. PMC: 3510660. DOI: 10.1016/j.ccr.2012.09.021. View

Fasullo M, Endres L . Nucleotide salvage deficiencies, DNA damage and neurodegeneration. Int J Mol Sci. 2015; 16(5):9431-49. PMC: 4463597. DOI: 10.3390/ijms16059431. View

Bartlett K, Eaton S . Mitochondrial beta-oxidation. Eur J Biochem. 2004; 271(3):462-9. DOI: 10.1046/j.1432-1033.2003.03947.x. View

Moon S, Huang C, Houlihan S, Regunath K, Freed-Pastor W, Morris 4th J . p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. 2018; 176(3):564-580.e19. PMC: 6483089. DOI: 10.1016/j.cell.2018.11.011. View

10.

DeBerardinis R, Cheng T . Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2009; 29(3):313-24. PMC: 2809806. DOI: 10.1038/onc.2009.358. View

11.

Mullen P, Yu R, Longo J, Archer M, Penn L . The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016; 16(11):718-731. DOI: 10.1038/nrc.2016.76. View

12.

Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M . G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002; 16(14):1779-91. PMC: 186403. DOI: 10.1101/gad.989402. View

13.

Mullarky E, Lucki N, Zavareh R, Anglin J, Gomes A, Nicolay B . Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc Natl Acad Sci U S A. 2016; 113(7):1778-83. PMC: 4763784. DOI: 10.1073/pnas.1521548113. View

14.

Huang M, Weiss W . Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013; 3(10):a014415. PMC: 3784814. DOI: 10.1101/cshperspect.a014415. View

15.

Olsen R, Otero J, Garcia-Lopez J, Wallace K, Finkelstein D, Rehg J . MYCN induces neuroblastoma in primary neural crest cells. Oncogene. 2017; 36(35):5075-5082. PMC: 5582212. DOI: 10.1038/onc.2017.128. View

16.

McTaggart S . Isoprenylated proteins. Cell Mol Life Sci. 2005; 63(3):255-67. PMC: 11136304. DOI: 10.1007/s00018-005-5298-6. View

17.

Anderson D . Cellular and molecular biology of neural crest cell lineage determination. Trends Genet. 1997; 13(7):276-80. DOI: 10.1016/s0168-9525(97)01187-6. View

18.

Meyer N, Penn L . Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-90. DOI: 10.1038/nrc2231. View

19.

Vasan K, Werner M, Chandel N . Mitochondrial Metabolism as a Target for Cancer Therapy. Cell Metab. 2020; 32(3):341-352. PMC: 7483781. DOI: 10.1016/j.cmet.2020.06.019. View

20.

Black J, Van Rechem C, Whetstine J . Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012; 48(4):491-507. PMC: 3861058. DOI: 10.1016/j.molcel.2012.11.006. View